Table 1.
Breast Pre-cancer Atlas Patient Cohorts with RNA-seq data and ipsilateral breast event used for outcome analysis.
| TBCRC | RAHBT | |||||
|---|---|---|---|---|---|---|
| DCIS without recurrence (N=95) | DCIS with DCIS Recurrence (N=66) | DCIS with Invasive Recurrence (N=55) | DCIS without recurrence (N=68) | DCIS with DCIS Recurrence (N=15) | DCIS with Invasive Recurrence (N=14) | |
| Year of Diagnosis | ||||||
| Median | 2009 | 2008 | 2006 | 2006 | 2008 | 2009 |
| Age at Diagnosis | ||||||
| Median | 54 | 54 | 50 | 52 | 53 | 52 |
| Mean (±SD) | 54.4 (±8.5) | 55.2 (±9.8) | 52.6 (±9.8) | 53.1 (±7.2) | 52.,5 (±6.0) | 55.1 (±11.1) |
| Grade | ||||||
| 1 | 5 [5.3%] | 6 [9.0%] | 3 [5.5%] | 18 [26.5%] | 4 [26.7%] | 3 [21.4%] |
| 2 | 37 [38.9%] | 26 [39.4%] | 19 [34.5%] | 28 [48.2%] | 4 [26.7%] | 8 [57.1%] |
| 3 | 53 [55.8%] | 34 [51.5%] | 33 [60.0%] | 22 [32.4%] | 7 [46.7%] | 2 [21.4%] |
| Pathologic Tumor Size | ||||||
| Median | 2.1 | 1.5 | 1.9 | |||
| Mean (±SD) | 2.7 (±1.9) | 2.2 (±2.0) | 2.8 (±2.6) | |||
| Marker Status | ||||||
| ER(+) | 60 [63.2%] | 41 [62.1%] | 37 [67.3%] | 55 [80.9%] | 8 [53.3%] | 12 [85.7%] |
| ER(−) | 35 [36.8%] | 25 [37.9%] | 18 [32.7%] | 13 [19.1%] | 7 [46.7%] | 2 [14.3%] |
| ER(+) Dx before 2000 | 0 | 2 [3.0%] | 4 [7.3%] | 3 [4.4%] | 0 | 3 [21.4%] |
| ER(+) Dx 2000 & after | 60 [63.2%] | 39 [59.1%] | 33 [60.0%] | 52 [76.5%] | 8 [53.3%] | 9 [64.3%] |
| ER(−) Dx before 2000 | 0 | 0 | 1 [1.8%] | 2 [2.9%] | 2 [13.3%] | 0 |
| ER(−) Dx 2000 & after | 35 [36.8%] | 25 [37.9%] | 17 [30.9%] | 11 [16.2%] | 5 [33.3%] | 2 [14.3%] |
| Treatment | ||||||
| Lumpectomy+Radiation | 58 [61.1%] | 40 [60.6%] | 22 [40.0%] | 6 [8.8%] | 2 [13.3%] | 2 [14.3%] |
| Lumpectomy−Radiation | 5 [5.3%] | 16 [25.2%] | 12 [21.8%] | 45 [66.2%] | 11 [73.3%] | 8 [57.1%] |
| Lumpectomy Radiation Unknown | 1 [1.1%] | 1 [1.5%] | 2 [3.6%] | 0 | 0 | 0 |
| Mastectomy | 31 [32.6%] | 9 [13.6%] | 19 [34.5%] | 17 [25.0%] | 2 [13.3%] | 4 [28.6%] |
| Time to Recurrence* (months) | ||||||
| Mean (±SD) | 105.7 (±37.0) | 52.7 (±39.9) | 71.2 (±43.9) | 139.8 (±52.7) | 54.9 (±40.4) | 73.4 (±68.4) |
| Median | 96 | 40 | 58 | 141 | 36 | 47 |
| Margins | ||||||
| Ink on tumor | 0 | 0 | 0 | 0 | 0 | 0 |
| <2mm | 27 [28.4%] | 28 [42.4%] | 17 [30.9%] | 15 [22.1%] | 4 [26.7%] | 6 [42.9%] |
| At least≥ 2mm | 37 [38.9%] | 25 [37.9%] | 21 [38.2%] | 11 [16.2%] | 4 [26.7%] | 1 [7.1%] |
| Clear, unknown mm | 31 [32.6%] | 13 [19.7%] | 17 [30.9%] | 42 [61.8%] | 7 [46.7%] | 7 [50.0%] |
| Race | ||||||
| White | 62 [65.2%] | 38 [57.6%] | 28 [50.9%] | 44 [64.7%] | 10 [66.7%] | 9 [64.3%] |
| Black | 22 [23.2%] | 21 [31.8%] | 22 [40.0%] | 24 [35.3%] | 5 [33.3%] | 5 [35.7%] |
| Asian | 2 [2.1%] | 1 [1.5%] | 2 [3.6%] | 0 | 0 | 0 |
| Pacific Islander | 0 | 1 [1.5%] | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 9 [9.5%] | 5 [7.6%] | 3 [5.5%] | 0 | 0 | 0 |
*
To end of follow-up for no recurrence. See also Table S1.